AVITA Medical specializes in regenerative medicine and has an innovative device for skin restoration that treats full-thickness skin defects and vitiligo. The RECELL device uses a patient's skin cells ...
VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care ...
VALENCIA, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, ...
We expect Avita’s RECELL to pose a significant challenge to the standard of care for larger burns, currently a skin graft sourced from elsewhere on the patient’s body. We believe Avita will be ...
The Food and Drug Administration signs off on a new wound treatment device by Avita Medical. Tech: Avita's Recell. Valencia-based Avita Medical Inc. has received FDA approval for a version of its ...
VALENCIA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today announced ...
VALENCIA, Calif. and MELBOURNE, Australia, June 07, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization ...
We have moved Medical technologies guidance 21 to become HealthTech guidance 356. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment ...
Regenerative medicine company Avita Medical Inc. raised AU$23 million (US$15 million) through a private placement on the Australian Securities Exchange (ASX:AVH) to support growth of its Recell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback